Havemeyer Place’s Regeneron Pharmaceuticals REGN Stock Holding History

Havemeyer Place’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-428	Closed	-$330K	–	671
2025 Q4	$330K	Buy	+428	New	+$291K	0.07%	383

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Havemeyer Place's REGN Position: Q1 2026 in Review

Havemeyer Place sold out of Regeneron Pharmaceuticals (REGN) in Q1 2026, closing a stake of 428 shares — an estimated $330K sold.

Havemeyer Place first reported a position in REGN in Q4 2025 and held it in 1 quarter. The position peaked at $330K in Q4 2025. 1,400 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Havemeyer Place reported no remaining Regeneron Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Havemeyer Place sold 428 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $330K.
Havemeyer Place first reported a position in Regeneron Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Havemeyer Place's Regeneron Pharmaceuticals position peaked at $330K in Q4 2025.
1,400 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Havemeyer Place's 13F filing for Q1 2026, filed 13 May 2026.